Dofetilide is under clinical development by Hyloris Pharmaceuticals and currently in Phase I for Atrial Flutter. According to GlobalData, Phase I drugs for Atrial Flutter have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dofetilide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dofetilide overview
HYCVS-033 (dofetilide) is under development for the treatment of atrial flutter and atrial fibrillation. The drug candidate is a reformulated product. It is administered through intravenous route. It acts by targeting potassium channel (KCN).
Hyloris Pharmaceuticals overview
Hyloris Pharmaceuticals (Hyloris) is a biopharmaceutical company that focuses on innovating, reinventing, and optimizing existing medications. The company’s pipeline products include Sotalol which treats atrial fibrillation; Aspirin IV for acute coronary syndrome; Milrinone treats advanced heart failure (LVAD); Dofetilide IV for atrial fibrillation; Metolazone IV treats congestive heart failure; HY-074 for acute coronary syndrome; HY-075 treats coronary heart disease. It collaborates with commercial partners for the early phases of product commercialization. Hyloris is headquartered in Liege, Belgium.
For a complete picture of Dofetilide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
